ATE175996T1 - Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren - Google Patents

Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren

Info

Publication number
ATE175996T1
ATE175996T1 AT95922078T AT95922078T ATE175996T1 AT E175996 T1 ATE175996 T1 AT E175996T1 AT 95922078 T AT95922078 T AT 95922078T AT 95922078 T AT95922078 T AT 95922078T AT E175996 T1 ATE175996 T1 AT E175996T1
Authority
AT
Austria
Prior art keywords
diagnosis
cancer
tyrosine phosphorylated
cells express
phosphorylated crkl
Prior art date
Application number
AT95922078T
Other languages
English (en)
Inventor
John H Groffen
Nora C Heisterkamp
Hoeve Johanna Ten
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Application granted granted Critical
Publication of ATE175996T1 publication Critical patent/ATE175996T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95922078T 1994-05-13 1995-05-12 Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren ATE175996T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/242,513 US5667981A (en) 1994-05-13 1994-05-13 Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein

Publications (1)

Publication Number Publication Date
ATE175996T1 true ATE175996T1 (de) 1999-02-15

Family

ID=22915067

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95922078T ATE175996T1 (de) 1994-05-13 1995-05-12 Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren

Country Status (10)

Country Link
US (1) US5667981A (de)
EP (1) EP0759986B1 (de)
JP (1) JPH10503365A (de)
AT (1) ATE175996T1 (de)
AU (1) AU691927B2 (de)
CA (1) CA2190161A1 (de)
DE (1) DE69507470D1 (de)
IL (1) IL113720A0 (de)
WO (1) WO1995031545A2 (de)
ZA (1) ZA953912B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309692B1 (en) 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
EP0878552A1 (de) 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molekularer Nachweis von chromosomalen Veränderungen
US6686165B2 (en) 1997-05-20 2004-02-03 Erasmus Universiteit Rotterdam Recognition of tumor-specific gene products in cancer
CA2290656C (en) 1997-05-20 2008-01-15 Erasmus Universiteit Rotterdam Recognition of tumour-specific gene products in cancer
AU3516899A (en) 1998-05-04 1999-11-23 Dako A/S Method and probes for the detection of chromosome aberrations
AU4567299A (en) * 1998-06-22 2000-01-10 Feshchenko, Elena A. C-cbl suppression of neoplastic transformation
US20080280771A1 (en) * 2000-02-08 2008-11-13 Regents Of The University Of Michigan Protein MicroarraySystem
US20050230315A1 (en) * 2003-01-13 2005-10-20 Regents Of The University Of Michigan Protein microarray system
US7110584B2 (en) * 2000-03-23 2006-09-19 Japan Science And Technology Corporation Cell lineage extracting method
CA2932756C (en) 2001-09-10 2020-07-07 Meso Scale Technologies, Llc Assay buffer, compositions containing the same, and methods of using the same
ATE443259T1 (de) 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
AU2003223494A1 (en) * 2002-04-05 2003-10-27 Cell Signaling Technology, Inc. Methods for detecting bcr-abl signaling activity in tissues using phospho- specific antibodies
US20060063156A1 (en) * 2002-12-06 2006-03-23 Willman Cheryl L Outcome prediction and risk classification in childhood leukemia
WO2004060055A1 (ja) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha Wt1遺伝子トランスジェニック動物
EP1682571A4 (de) * 2003-10-27 2006-12-06 Medvet Science Pty Ltd Zweizähniges motiv und anwendungsverfahren
WO2006086111A2 (en) * 2005-02-10 2006-08-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
CN102105487A (zh) * 2008-06-20 2011-06-22 得克萨斯大学体系董事会 靶向crkl的肽
WO2012030738A2 (en) * 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
US9637523B2 (en) 2012-08-31 2017-05-02 Westfaelische Wilhelms-Universitaet Muenster Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
JP7300642B2 (ja) * 2019-06-14 2023-06-30 国立大学法人浜松医科大学 特発性肺線維症の予後予測方法
CN115991789B (zh) * 2022-07-14 2024-06-04 华中科技大学 一种基于sh2超亲体的融合蛋白及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH082799B2 (ja) * 1987-03-06 1996-01-17 秀雄 麦島 骨髄線維症治療剤
WO1993003377A1 (en) * 1991-07-31 1993-02-18 Ziltener Hermann J Method for the detection of phosphotyrosine residues
US5352660A (en) * 1991-10-31 1994-10-04 Mount Sinai Hospital Corporation Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system

Also Published As

Publication number Publication date
DE69507470D1 (de) 1999-03-04
EP0759986B1 (de) 1999-01-20
AU2689095A (en) 1995-12-05
CA2190161A1 (en) 1995-11-23
EP0759986A1 (de) 1997-03-05
IL113720A0 (en) 1995-10-31
WO1995031545A3 (en) 1996-08-01
US5667981A (en) 1997-09-16
ZA953912B (en) 1996-01-16
AU691927B2 (en) 1998-05-28
JPH10503365A (ja) 1998-03-31
WO1995031545A2 (en) 1995-11-23

Similar Documents

Publication Publication Date Title
DE69507470D1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
WO1998035693A3 (en) Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
ATE198513T1 (de) Ptpalpha-bestimmung in der tumordiagnose und - prognose
Lee et al. Twist1 is a key regulator of cancer-associated fibroblasts
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
DE69737788D1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
AU9779498A (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
ATE332979T1 (de) Detektion von änderungen von tumor-suppressor genen zur diagnose von krebs
Zhao et al. Expression profile of genes associated with antimetastatic gene: nm23‐Mediated metastasis inhibition in breast carcinoma cells
DE60032784D1 (de) Markerproteine für prostatakrebs
Fang et al. High levels of CD 20 expression predict good prognosis in chronic lymphocytic leukemia
ATE152629T1 (de) Diagnose von krebs-metastasen durch das mts-1 gen
NO982588D0 (no) FremgangsmÕte for diagnose og behandling av plate epizelkarsinom
BR0303092A (pt) Portfólio para prognóstico de câncer de mama
EP1012338A4 (de) Ein tumorsuppressor namens ts10q23.3
ATE363916T1 (de) Die expression von cyclin g1 in tumoren
Sartini et al. Differential expression of nicotinamide N-methyltransferase in cutaneous keratoacanthoma and squamous cell carcinoma: An immunohistochemical study
BR0012301A (pt) Inibidores de crescimento de células epiteliais
ATE520031T1 (de) Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen
WO2003029482A3 (en) Diagnosing, treating, and preventing cancer using cables
BR9815776A (pt) Anticorpos monoclonais anti-tag-72 humanizados com alta afinidade
TR200200691T2 (tr) Akciğer kanserinin tedavisine ve teşhisine ilişkin bileşimler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties